JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$5.47B |
| 2 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$3.17B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$2.05B |
| 4 |
Amazon
AMZN
|
+$1.96B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.6B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$1.72B |
| 2 |
Vanguard Intermediate-Term Treasury ETF
VGIT
|
+$1.31B |
| 3 |
UnitedHealth
UNH
|
+$1.26B |
| 4 |
Automatic Data Processing
ADP
|
+$1.17B |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$1.08B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.28% |
| 2 | Technology | 17.17% |
| 3 | Healthcare | 10.79% |
| 4 | Financials | 9.36% |
| 5 | Consumer Discretionary | 8.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
6151
Enliven Therapeutics
ELVN
$3.44B
| $2K | ﹤0.01% |
+94
| New | +$1.91K |
2023 Q1
0 quarters
|
|
6152
Entera Bio
ENTX
$495M
| $2K | ﹤0.01% |
+1,868
| New | +$1.87K |
2023 Q1
0 quarters
|
|
|
FBZ
6153
DELISTED
First Trust Brazil AlphaDEX Fund
FBZ
| $2K | ﹤0.01% |
+238
| New | +$2.5K |
2023 Q1
0 quarters
|
|
|
DMRA
6154
Damora Therapeutics
DMRA
$1.27B
| $2K | ﹤0.01% |
34
| – | – |
2022 Q1
4 quarters
|
|
|
GOOS
6155
Canada Goose Holdings
GOOS
$748M
| $2K | ﹤0.01% |
82
| – | – |
2017 Q2
23 quarters
|
|
6156
Direxion Daily S&P 500 High Beta Bull 3X ETF
HIBL
$85M
| $2K | ﹤0.01% |
+77
| New | +$2.48K |
2023 Q1
0 quarters
|
|
6157
Werewolf Therapeutics
HOWL
$45.1M
| $2K | ﹤0.01% |
748
| – | – |
2021 Q2
7 quarters
|
|
|
IDE
6158
Voya Infrastructure, Industrials and Materials Fund
IDE
$184M
| $2K | ﹤0.01% |
256
-2,717
| -91% | -$26.4K |
2022 Q4
1 quarter
|
|
6159
VanEck Intermediate Muni ETF
ITM
$2.02B
| $2K | ﹤0.01% |
+42
| New | +$1.94K |
2023 Q1
0 quarters
|
|
6160
Quadratic Interest Rate Volatility and Inflation Hedge ETF
IVOL
$243M
| $2K | ﹤0.01% |
110
-2,147,631
| -100% | -$47.4M |
2022 Q1
4 quarters
|
|
6161
Standard BioTools
LAB
$292M
| $2K | ﹤0.01% |
1,311
| – | – |
2016 Q4
25 quarters
|
|
6162
LiveWire
LVWR
$322M
| $2K | ﹤0.01% |
+245
| New | +$1.58K |
2023 Q1
0 quarters
|
|
|
MSD
6163
Morgan Stanley Emerging Markets Debt Fund
MSD
$136M
| $2K | ﹤0.01% |
+280
| New | +$1.88K |
2023 Q1
0 quarters
|
|
6164
Nuveen California Municipal Value Fund
NCA
$279M
| $2K | ﹤0.01% |
180
-1,465
| -89% | -$12.9K |
2022 Q4
1 quarter
|
|
6165
Nuwellis
NUWE
$2.2M
| – | – |
0
| – | – |
2021 Q1
8 quarters
|
|
6166
Tradr 1.25X NVDA Bear Daily ETF
NVDS
$8.89M
| $2K | ﹤0.01% |
+2
| New | +$3.61K |
2023 Q1
0 quarters
|
|
6167
Oxford Square Capital
OXSQ
$138M
| $2K | ﹤0.01% |
579
+346
| +148% | +$1.18K |
2022 Q4
1 quarter
|
|
6168
Palisade Bio
PALI
$251M
| $2K | ﹤0.01% |
42
-32
| -43% | -$1.13K |
2022 Q4
1 quarter
|
|
|
PGP
6169
PIMCO Global StockPLUS & Income Fund
PGP
$97.6M
| $2K | ﹤0.01% |
+217
| New | +$1.65K |
2023 Q1
0 quarters
|
|
|
PHX
6170
DELISTED
PHX Minerals
PHX
| $2K | ﹤0.01% |
836
-306
| -27% | -$973 |
2017 Q3
22 quarters
|
|
6171
State Street SPDR ICE Preferred Securities ETF
PSK
$641M
| $2K | ﹤0.01% |
+71
| New | +$2.49K |
2023 Q1
0 quarters
|
|
6172
Research Frontiers
REFR
$25.4M
| $2K | ﹤0.01% |
1,043
| – | – |
2020 Q2
11 quarters
|
|
|
SATX
6173
DELISTED
SatixFy Communications
SATX
| $2K | ﹤0.01% |
3,300
+3,238
| +5,223% | +$8.46K |
2022 Q4
1 quarter
|
|
|
SOR
6174
Source Capital
SOR
$370M
| $2K | ﹤0.01% |
+53
| New | +$2.02K |
2023 Q1
0 quarters
|
|
6175
State Street SPDR Portfolio Aggregate Bond ETF
SPAB
$9.78B
| $2K | ﹤0.01% |
+72
| New | +$1.84K |
2023 Q1
0 quarters
|
|
Similar funds
JP Morgan Chase's Q1 2023 Portfolio in Review
As of Q1 2023, JP Morgan Chase held 7,579 positions worth $821B, up 8.2% from $759B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
JP Morgan Chase's Q1 2023 filing shows 751 new, 3,314 increased, 2,056 reduced and 652 closed positions. Its largest new stake was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M. The largest sale was Eli Lilly, an estimated $1.72B.
By sector, the portfolio is most concentrated in Miscellaneous at 27% of assets, up from 27% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q1 2023 buy was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M.
- JP Morgan Chase added most to JPMorgan BetaBuilders Europe ETF in Q1 2023, an estimated $5.47B increase.
- JP Morgan Chase's biggest Q1 2023 reduction was Eli Lilly, cutting an estimated $1.72B.
- JP Morgan Chase fully exited IAA, Inc. Common Stock in Q1 2023, selling an estimated $155M.
- JP Morgan Chase's ten largest holdings make up 17% of its $821B portfolio in Q1 2023.
- JP Morgan Chase opened 751 new positions and closed 652 in Q1 2023.
- JP Morgan Chase's portfolio value rose 8.2% quarter-over-quarter to $821B.
Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.